INO — Inovio Pharmaceuticals, Inc.
$1.43
$-0.03 (-2.05%)
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Market Cap
$267.85M
Forward P/E
-47.7x
52-Week Range
N/A
INO Price History
Revenue vs. Net Income
$65.3K
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$88.9M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-277.2%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.5x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
437.2%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+72.6%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
